Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tiago Fauth Reiterated (SPRB) at Buy and Held Target at $4 on, Mar 17th, 2023
Tiago Fauth of Credit Suisse, Reiterated "Spruce Biosciences, Inc." (SPRB) at Buy and Held Target at $4 on, Mar 17th, 2023.
Tiago has made no other calls on SPRB in the last 4 months.
There are 2 other peers that have a rating on SPRB. Out of the 2 peers that are also analyzing SPRB, 0 agree with Tiago's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Tiago
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $8 on, Monday, February 13th, 2023
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $8 on, Thursday, November 17th, 2022
